US 9,810,691 B2
Biomarker for detecting cancer
Robert Bresalier, Missouri City, TX (US); Nachman Mazurek, Houston, TX (US); and James C. Byrd, Spring, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Appl. No. 14/350,824
Filed by THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
PCT Filed Oct. 10, 2012, PCT No. PCT/US2012/059567
§ 371(c)(1), (2) Date Apr. 10, 2014,
PCT Pub. No. WO2013/055799, PCT Pub. Date Apr. 18, 2013.
Claims priority of provisional application 61/545,675, filed on Oct. 11, 2011.
Prior Publication US 2014/0378558 A1, Dec. 25, 2014
Int. Cl. G01N 33/574 (2006.01)
CPC G01N 33/57419 (2013.01) [G01N 2333/4724 (2013.01)] 23 Claims
 
1. A method for detection or diagnosis of colorectal cancer in a subject, comprising:
(a) obtaining a serum sample of the subject;
(b) desialylating the serum sample;
(c) contacting the desialylated serum sample with an antibody that binds haptoglobin to form a complex;
(d) quantitating the complex with a detectable lectin that binds galactose in order to detect or diagnose colorectal cancer using a quantitative immune-detection assay, wherein the presence of a galactose-containing haptoglobin glycoform is associated with the presence of colorectal cancer, wherein the quantitative immune-detection assay is not a Western blot, and wherein the detectable lectin that binds galactose is selected from the group consisting of Ricinus communis lectin, Sophora japonica lectin, Datura stramonium lectin, Erythrina cristagalli lectin, and Lycopersicon esculentum lectin; and
(e) administering an anticancer therapy to the subject having colorectal cancer.